VelosBio is a clinical-stage biopharmaceutical company developing first-in-class therapeutics that target ROR1, a cell-surface antigen expressed across hematologic and solid tumor malignancies. Its lead candidate, VLS-101, is a ROR1-directed antibody-drug conjugate currently in a first-in-human Phase 1 trial in patients with relapsed or refractory hematologic cancers, with solid tumor studies scheduled to begin later this year. The company is also advancing a pipeline of next-generation ROR1-directed ADCs and bispecific antibodies. VelosBio plans to use the recent financing to further clinical development of VLS-101 and to expand its ROR1-directed pipeline. Since its founding in 2017 the company has raised $202 million in gross private financings, including an oversubscribed $137 million Series B. VelosBio is headquartered in San Diego and emphasizes expanding its team of scientists and researchers to develop targeted oncology therapies. VelosBio is a US-based near-term clinical-stage biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) for hematological cancers and solid tumors. Its core product approach is ADCs, a targeted therapy designed to selectively deliver cytotoxic agents to cancer cells while limiting effects on healthy tissue. The company is led by CEO Dave Johnson and EVP of Development and CMO Langdon Miller, MD. VelosBio raised $58M in a Series A to complete nonclinical development and advance its lead programs into clinical studies. The financing was co-led by Arix Bioscience and Sofinnova Ventures, with participation from Pappas Ventures, Chiesi Ventures and existing investors Takeda Ventures and Decheng Capital. Arix committed $11M for an 11.2% ownership stake and Arix Investment Director Mark Chin will join VelosBio's board as part of the transaction.

Total raised

$195M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2020